2CUREX AB SEK-10 (F:2QE) — Stock Price
2CUREX AB SEK-10 (F:2QE) is currently trading at €0.04 EUR, down 25.20% today. Over the past 52 weeks, shares have ranged between €0.04 and €0.25. This page tracks 2CUREX AB SEK-10's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. To see how efficiently this company converts equity into cash flow, see cash efficiency ratio of 2CUREX AB SEK-10.
2CUREX AB SEK-10 (2QE) Stock Price Chart — Daily History & Trading Volume
The chart below tracks 2CUREX AB SEK-10's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
2CUREX AB SEK-10 Income Statement — Revenue, Profit & Earnings by Year
2CUREX AB SEK-10's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Revenue | €0.00 | €0.00 | €90.00K | €0.00 |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Research & Development | — | — | — | — |
| SG&A | — | — | €12.38 Million | €11.86 Million |
| Total Operating Expenses | €5.17 Million | €2.83 Million | €32.22 Million | €22.80 Million |
| Operating Income | €-5.17 Million | €-2.83 Million | €-32.13 Million | €-22.80 Million |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | €2.00K | €5.00K | €0.00 | €104.00K |
| Income Before Tax | €-4.55 Million | €-38.38 Million | €-29.77 Million | €-22.48 Million |
| Income Tax Expense | — | — | — | — |
| Net Income | €-4.55 Million | €-38.38 Million | €-29.77 Million | €-18.94 Million |
2CUREX AB SEK-10 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes 2CUREX AB SEK-10's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Total Assets | €7.70 Million | €7.07 Million | €47.66 Million | €79.16 Million |
| Total Current Assets | €7.70 Million | €2.07 Million | €46.66 Million | €78.47 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | — | — | — | — |
| Net Receivables | €2.61 Million | €143.00K | €0.00 | — |
| Inventory | — | — | — | — |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | €3.03 Million | €533.00K | €4.62 Million | €4.82 Million |
| Total Current Liabilities | €3.03 Million | €533.00K | €4.62 Million | €4.82 Million |
| Long-term Debt | — | — | — | — |
| Net Debt | — | — | — | — |
| Total Stockholder Equity | €4.68 Million | €6.54 Million | €43.03 Million | €74.34 Million |
| Retained Earnings | €-111.64 Million | €-107.09 Million | €-29.77 Million | €-18.94 Million |
2CUREX AB SEK-10 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how 2CUREX AB SEK-10 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Operating Cash Flow | €-4.63 Million | €-1.95 Million | €-27.98 Million | €-18.43 Million |
| Capital Expenditures | €0.00 | €17.00K | €541.00K | €32.00K |
| Free Cash Flow | €-4.63 Million | €-1.95 Million | €-28.52 Million | €-18.46 Million |
| Investing Cash Flow | — | — | — | — |
| Financing Cash Flow | — | — | — | — |
| Dividends Paid | — | — | — | — |
| Stock-Based Compensation | — | €543.00K | €1.22 Million | — |
| Depreciation | — | €312.00K | €311.00K | €353.00K |
| Change in Cash | €3.68 Million | €-37.86 Million | €-28.52 Million | €14.09 Million |
2CUREX AB SEK-10 Earnings History — EPS Actual vs. Analyst Estimates
Track 2CUREX AB SEK-10's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 26, 2026 | — | — | — |
| Aug 21, 2025 | — | — | — |
| Feb 27, 2025 | — | — | — |